Stimulation of renal proximal tubule (PT) transport by angiotensin II (Ang II) is critical for regulation of BP. Notably, in rats, mice, and rabbits, the regulation of PT sodium transport by Ang II is biphasic: transport is stimulated by picomolar to nanomolar concentrations of Ang II but inhibited by nanomolar to micromolar concentrations of Ang II. However, little is known about the effects of Ang II on human PT transport. By functional analysis with isolated PTs obtained from nephrectomy surgery, we found that Ang II induces a dose-dependent profound stimulation of human PT transport by type 1 Ang II receptor (AT 1 )-dependent phosphorylation of extracellular signal-regulated kinase (ERK). In PTs of wild-type mice, the nitric oxide (NO) /cGMP/cGMP-dependent kinase II (cGKII) pathway mediated the inhibitory effect of Ang II. In PTs of cGKII-deficient mice, the inhibitory effect of Ang II was lost, but activation of the NO/cGMP pathway failed to phosphorylate ERK. Conversely, in human PTs, the NO/cGMP pathway mediated the stimulatory effect of Ang II by phosphorylating ERK independently of cGKII. These contrasting responses to the NO/cGMP pathway may largely explain the different modes of PT transport regulation by Ang II, and the unopposed marked stimulation of PT transport by high intrarenal concentrations of Ang II may be an important factor in the pathogenesis of human hypertension. Additionally, the previously unrecognized stimulatory effect of the NO/cGMP pathway on PT transport may represent a human-specific therapeutic target in hypertension.
Among the several regulatory systems for BP, the renin-angiotensin system (RAS) plays a key role. Angiotensin II (Ang II) can regulate BP by type 1 (AT 1 ) Ang II receptors in either the kidney or the extrarenal tissues. Using a kidney cross-transplantation strategy, Crowley et al. 1 revealed that AT 1A in the kidney is critical for the pathogenesis of Ang II-mediated hypertension and its cardiovascular complications. Crowley et al. 1 also showed that genetic abrogation AT 1A in renal proximal tubules (PTs) alone is sufficient to reduce BP and provide substantial protection against Ang II-induced hypertension in mice, suggesting that the stimulation of PTsodium transport by Ang II has a major impact on BP regulation. 2 Paradoxically, however, the regulation of PT sodium transport by Ang II is biphasic: transport is stimulated by low (picomolar to nanomolar) concentrations of Ang II, whereas it is inhibited by high (nanomolar to micromolar) concentrations of Ang II. 3, 4 Notably, the concentrations of Ang II within the kidney are known to be much higher than the concentrations in plasma, although the measurement of urinary Ang II may be less valuable. 5, 6 Therefore, the inhibitory effect of high concentrations of Ang II could also have some physiologic relevance to the regulation of in vivo PT transport. 5 Ang II regulates the major PT sodium transporters the apical Na + /H + exchanger isoform 3 (NHE3), the basolateral Na + -HCO 3 2 cotransporter (NBCe1), and the basolateral Na + /K + ATPase in the biphasic manner. [7] [8] [9] [10] [11] [12] Although controversial results had been reported of the receptor subtype(s) mediating the biphasic effects of Ang II, 13, 14 the studies using isolated PTs obtained from AT 1A knockout (KO) mice have established that AT 1A mediates both the stimulatory and inhibitory effects of Ang II. 11, 15 The stimulation by Ang II has been attributed to the activation of protein kinase C and/or the decrease in the intracellular cAMP concentration, resulting in the activation of extracellular signal-regulated kinase (ERK) pathway. [16] [17] [18] However, the inhibition by Ang II has been attributed to the activation of the phospholipase A 2 /arachidonic acid/5,6-epoxyeicosatrienoic acid (EET) pathway and/or the nitric oxide (NO)/guanosine 39,59-cyclic monophosphate (cGMP) pathway. 7, 12, 17, 19 Although the biphasic regulation of PT transport by Ang II has been reported in several species, such as rats, mice, and rabbits, 3, 4, 15 whether Ang II has similar biphasic effects on human PT transport remains unknown. Moreover, the signaling mechanisms mediating the Ang II actions on human kidney have not been clarified at all.
To clarify these issues, we examined the effects of Ang II on isolated human PTs obtained from nephrectomy surgery. Unexpectedly, our findings revealed that Ang II, unlike in the other species, dose-dependently stimulates human PT transport. The different modes of transport regulation by Ang II can be largely explained by the contrasting roles of the NO/cGMP pathway, which as a downstream mediator of Ang II signaling in PTs, is stimulatory in human subjects but inhibitory in the other species. The unopposed marked stimulation of PT transport by the high local concentrations of Ang II may be an important factor in the pathogenesis of human hypertension. Furthermore, the stimulatory effect of the NO/cGMP pathway on human PT transport may represent a previously unrecognized therapeutic target of hypertension.
RESULTS
We first examined the effects of Ang II on NBCe1 activity in isolated luminally collapsed human PTs. This preparation is suitable for the identification of biphasic effects of Ang II on NBCe1 mediated through basolateral AT 1 receptors. 11, 15, 17, 19 The basal NBCe1 activity (60.062.3 mM/min, n=70) determined from 22 persons ages 59.362.0 years was lower than the activity (82.262.2 mM/min, n=41) from 11 mice ages 9.160.8 weeks. Unlike Ang II in mouse or rabbit PTs, [9] [10] [11] 17 Ang II in human PTs induced a dose-dependent marked stimulation of the NBCe1 activity ( Figure 1A 11, 20 The stimulation of NBCe1 by Ang II was largely suppressed by a specific AT 1 inhibitor valsartan ( Figure 1B) and completely suppressed by an mitogen-activated protein kinase/ERK (MEK) inhibitor PD98059 ( Figure 1C) , indicating that the AT 1 /MEK/ERK pathway mediates the stimulatory effect of Ang II. Indeed, Ang II dose-dependently stimulated ERK phosphorylation in human kidney cortex (Figure 1, D and E) .
Using luminally perfused human PTs, we next found that Ang II added to bath perfusate dose-dependently stimulated not only the apical NHE3 activity but also, the rate of sodium-dependent bicarbonate absorption (JHCO 3 2 ), as shown in Figure 1 , F and G. Ang II added to luminal perfusate also dose-dependently stimulated JHCO 3 2 ( Figure 1H ), suggesting that both basolateral and luminal AT 1 receptors mediate the dose-dependent marked stimulatory effect of Ang II on net human PT transport.
To clarify the mechanism underlying the loss of inhibitory effect of Ang II in human PTs, we examined the role of phospholipase A 2 /arachidonic acid/5,6-EET pathway, which represents one of the inhibitory mediators of Ang II effects in the other species. 7, 17 Both arachidonic acid and 5,6-EET failed to inhibit the human NBCe1 activity (Supplemental Figure 1) , although they did inhibit the mouse NBCe1 activity as reported. 11, 17 To further clarify the mechanism(s) underlying the different modes of PT transport regulation by Ang II, we next examined the role of the NO/cGMP pathway, which might also mediate the inhibitory effect of Ang II in the other species. 12, 18 As previously reported, 11, 17 Ang II had biphasic effects on NBCe1 activity in mouse PTs (Figure 2A ). In the presence of an NO synthase (NOS) inhibitor L-nitro-arginine methyl ester (L-NAME), however, the inhibitory effect of Ang II was lost, and all of the concentrations of Ang II now induced the similar stimulation ( Figure 2B ). In the presence of L-NAME, all of the concentrations of Ang II also induced the similar magnitude of ERK phosphorylation ( Figure 2, C and D ). An NO donor sodium nitroprusside (SNP) dose-dependently inhibited the NBCe1 activity ( Figure 2E) Figure  2F ). Furthermore, a cell-permeable cGMP analog 8Br-cGMP inhibited the NBCe1 activity ( Figure 2G ). These results indicate that the NOS/NO/sGC/cGMP pathway mediates the inhibitory effect of Ang II in mouse PTs. Consistent with this view, 8Br-cGMP and SNP failed to stimulate ERK phosphorylation in mouse kidney cortex ( Figure 2, H and I) .
Although the NO/cGMP pathway is generally thought to inhibit PT transport, 21,22 controversial results have been also reported. 23 Therefore, we examined the effects of NO in rat PTs. As in mouse PTs, Ang II had biphasic effects on NBCe1 activity in rat PTs ( Figure 3A) . Furthermore, SNP significantly inhibited the NBCe1 activity ( Figure 3B ), indicating that NO is also inhibitory in rat PTs.
In contrast to the results obtained in mouse and rat PTs, we found that the NOS/NO/sGC/cGMP pathway mediates the stimulatory effect of Ang II in human PTs. Thus, L-NAME completely suppressed the stimulatory effect of Ang II ( Figure 4A ). SNP dose-dependently stimulated the NBCe1 activity ( Figure 4B ). Although ODQ totally suppressed the stimulation by 10 26 M Ang II ( Figure 4C ), 8Br-cGMP significantly stimulated the NBCe1 activity ( Figure 4D ). Consistent with the stimulatory role of the NO/cGMP pathway, 8Br-cGMP and SNP stimulated ERK phosphorylation in human kidney cortex ( Figure 4 , E and F). Furthermore, PD98059 completely suppressed the stimulation by 10 23 M SNP ( Figure 4G ). These results indicate that the ERK activation by the NOS/NO/sGC/cGMP pathway mediates the stimulatory effect of Ang II in human PTs.
Among several potential signaling pathways, cGMPdependent protein kinases may represent the principle mediator of cGMP signaling. 24 Therefore, we examined the roles of cGKII, the only cGK isoform expressed in PTs. 25 The analyses by RT-PCR and immunohistochemistry, indeed, confirmed the cGKII expression in PTs of human subjects and wildtype (WT) mice (Supplemental Figure 2) . In PTs of cGKII KO mice, 26 however, the cGKII expression was completely absent. A cGK inhibitor KT5823 failed to affect the stimulation by 10 26 M Ang II in human PTs ( Figure 5A ). However, KT5823 converted the inhibition by 10 26 M Ang II to the stimulation in WT mouse PTs ( Figure 5B ). Furthermore, the inhibitory effect of Ang II was lost, and all of the Ang II concentrations induced the similar stimulation in cGKII KO mouse PTs ( Figure 5C ). These results indicate that, although cGKII mediates the inhibitory effect of Ang II in mouse PTs, it is not involved in Ang II signaling in human PTs. The phosphorylation status of GSK-3b, the in vitro and in vivo substrate of cGKII, 27 also supported the lack of cGKII activation by the Ang II/NO/cGMP pathway in human PTs (Supplemental Figure 3) . Thus, Ang II dose-dependently stimulated GSK-3b phosphorylation in WT mouse kidney cortex as expected. However, Ang II failed to stimulate GSK-3b phosphorylation in human and cGKII KO mouse kidneys. Furthermore, 8Br-cGMP and SNP stimulated GSK-3b phosphorylation in WT mouse kidneys but not human and cGKII KO mouse kidneys. Unlike SNP and 8Br-cGMP in human PTs, SNP ( Figure 5D ) and 8Br-cGMP ( Figure 5E ) failed to stimulate the NBCe1 activity in cGKII KO mouse PTs. Moreover, 8Br-cGMP and SNP failed to stimulate ERK phosphorylation in cGKII KO mouse kidney cortex (Figure 5, F and G) . These results indicate that the removal of cGKII alone from mouse PTs cannot reproduce the dose-dependent stimulatory effect of Ang II in human PTs that is based on the NO/cGMP-mediated ERK activation.
cGMP might also work through the cAMP/protein kinase A pathway through either crossactivation or its effects on cyclic nucleotide phosphodiesterases. 24 In human PTs, however, a nonselective inhibitor of phosphodiesterases, isobutylmethylxanthine, did not affect the stimulatory effects of 10 26 M Ang II ( Figure 6A ) or 10 23 M SNP ( Figure 6B ). Moreover, dibutyryl cAMP at 2310 25 M did not affect the NBCe1 activity ( Figure 6C ). These results do not support the view that the cAMP/protein kinase A pathway mediates Ang II/NO/cGMP-dependent stimulation in human PTs.
Finally, we examined Ang II concentration in the human kidney cortex. Mean Ang II concentration was 2.060.4 pmol/g tissue (n=8), confirming the high intrarenal Ang II concentration in human subjects. 28 
DISCUSSION
This study revealed that Ang II has concentration-dependent marked stimulatory effect on human PT transport. The lack of inhibition by arachidonic acid and 5,6-EET may be at least partially involved in the loss of inhibitory effect of Ang II in human PTs. Remarkably, however, the responses to the NOS/NO/sGC/cGMP pathway differed even more sharply, being inhibitory through cGKII activation in mouse PTs but stimulatory through ERK activation in human PTs. These results indicate that the opposite responses to the NO/cGMP pathway may be largely responsible for the difference in PT transport regulation by Ang II among human and other species.
PTs are known to express endothelial NOS, inducible NOS, and neuronal NOS, and they can produce substantial amounts of NO in response to a variety of stimuli. 21, 22 NO is generally considered to be inhibitory on PT transport. 21, 22 Moreover, several studies reported that the NO/cGMP pathway mediates the inhibitory effect of Ang II on PT transport. 12, 18 In the present study, the NOS inhibitor L-NAME, the sGC inhibitor ODQ, and the cGK inhibitor KT5823 converted the inhibition by 10 26 M Ang II to the stimulation in WT mouse PTs. Furthermore, the NO donor SNP and 8Br-cGMP inhibited the NBCe1 activity in WT mouse PTs. SNP was also inhibitory in rat PTs. In cGKII KO mouse PTs, however, the inhibitory effects of SNP and 8Br-cGMP were lost, and all of the concentrations of Ang II induced the similar stimulation. These results indicate that the NO/cGMP/cGKII pathway mediates the inhibitory effect of Ang II in mouse PTs. The cGKII-dependent GSK-3b phosphorylation by Ang II, SNP, and 8Br-cGMP in mouse kidney cortex also supported this view.
In human PTs, by contrast, the ERK-dependent stimulatory effect of Ang II was completely suppressed by L-NAME and ODQ. Both SNP and 8Br-cGMP stimulated the NBCe1 activity, and the stimulatoryeffect ofSNPwas dependent onERKactivation. These results indicate that the NO/cGMP/ERK pathway mediates the dose-dependent stimulatory effect of Ang II in human PTs. Although human PTs did express cGKII, KT5823 failed to affect the stimulation by Ang II. Moreover, Ang II, SNP, and 8Br-cGMP stimulated ERK phosphorylation without inducing GSK-3b phosphorylation, suggesting that cGKII is not involved in the Ang II/NO/cGMP-mediated ERK activation in human PTs. The AT 1 /MEK/ERK pathway also works as a stimulatory signal in mouse PTs. 17, 19 However, the difference in kinetics for Ang IImediated ERK phosphorylation shown in this study also supports a view that the mechanisms of Ang II-mediated ERK activation are different in mouse and human PTs.
Although the NO/cGMP pathway may work as either stimulatory or inhibitory on ERK depending on the cell types, 29, 30 a puzzling question remains unanswered as to why the NO/cGMP pathway, acting as the downstream mediator of Ang II signaling, exerts the contrasting effects on PT transport in humans and other species. However, several previous studies have suggested that such species differences may, indeed, exist in the roles of the NO/cGMP pathway in renal sodium handling. For example, chronic salt loading into normal rats and mice induces an enhanced renal NO synthesis, which facilitates sodium excretion and preservation of normal BP. [31] [32] [33] NO deficiency may be causally linked to the development of hypertension in salt-sensitive Dahl rats on high-salt diet. 34 In healthy human subjects, however, high sodium intake (200 mmol/d) for 5 days decreased plasma renin activity and aldosterone concentrations but did not change renal NO synthesis. 35 Ultra-high sodium intake (400 mmol/d) for 3 days also failed to increase renal NO synthesis. 36 Furthermore, the NO donor SNP induces marked diuretic and natriuretic responses in conscious rats. 35 In human subjects, by contrast, SNP fails to induce significant natriuresis, 37 and another SNP donor nitroglycerin even induces sodium retention and plasma volume expansion. 38 Thus, the role of NO/cGMP in adaptive natriuretic response to salt loading has been consistently confirmed in experimental animals but not human subjects. It is tempting to speculate that the contrasting effects of NO/cGMP on PT transport revealed in the present study may be at least partially responsible for these conflicting results. It remains to be determined whether the similar species differences also exist in the effects of NO/cGMP on sodium transport in the other nephron segments, such as thick ascending limb and collecting ducts. 39 In 1977, Harris and Young 3 found that Ang II regulates rat PT transport in a biphasic way. Since that time, the biphasic effects of Ang II on PT transport have been confirmed in rabbits and mice as well. 4, [9] [10] [11] 15 The major role of Ang II is thought to be the stimulation of PT transport. 2 However, as we confirmed in this study, intrarenal concentration of Ang II (approximately 2 pmol/g tissue) is much higher than the concentration in plasma (approximately 20 fmol/ml) in human subjects. 28, 40 High intrarenal concentrations of Ang II were also found in mice (approximately 0.5 pmol/g tissue) and rats (approximately 0.1 pmol/g tissue). 41, 42 Moreover, the high-salt diet paradoxically enhances the luminal Ang II concentration in rat PTs. 43 Therefore, the inhibitory effect of high concentrations of Ang II could also have some physiologic significance. 5 For example, the inhibitory effect of Ang II may work to prevent unwarranted sequences, such as exaggerated volume expansion, cell hypertrophy, or cell damages. However, the unopposed stimulation of human PT transport by high local concentrations of Ang II suggests that the roles of Ang II in volume homeostasis and BP regulation may be even more important in human subjects than other species. Humans may evolutionally acquire this kind of atypical response to Ang II to adapt to life-threatening salt deprivation. The dose-dependent ERK activation by Ang II observed in human but not mouse PTs suggests that the effects of Ang II on cell survival or differentiation may be also somehow different in human subjects and other species. Interestingly, gene mutations in any components of RAS cause renal tubular dysgenesis characterized by absence or quasiabsence of differentiated PTs in human subjects, whereas inactivation of RAS genes in mice or rats does not induce renal tubular dysgenesis. 44 In summary, we identified that, unlike in other species, Ang II in humans dose-dependently stimulates PT transport. This atypical mode of PT transport regulation by Ang II dependent on the NO/cGMP/ERK pathway may represent a humanspecific therapeutic target in hypertension.
CONCISE METHODS

Measurements of NBCe1 and NHE3 Activities
All animal procedures were in accordance with local institutional guidelines. Thin slices of kidney cortex were obtained from WT and cGKII KO mice, both of C57BL/6 background, 26 or Wistar rats as described. 45 Human kidney cortex tissues were obtained during the unilateral nephrectomy for renal carcinoma. The institutional review board of the University of Tokyo School of Medicine approved the study, and written informed consent was obtained from all subjects as described. 45 For the analysis of NBCe1 activity, the PT (S2 segment) fragment was microdissected manually and transferred to a perfusion chamber mounted on an inverted microscopy. Both ends of the tubule were sucked into two holding pipettes. To avoid the influence of luminal transporters, the luminally collapsed tubule was used as described. 11, 17, 45 The tubule was incubated with the acetoxymethylester form of a pH-sensitive fluorescence dye 29,79-bis (carboxyethyl)-5(6)-carboxyfluorescein (Dojindo), and cell pH was monitored with a photometry system (OSP-10; Olympus). Prewarmed (38°C) DMEM, equilibrated with 5% CO 2 /95% O 2 gas and supplemented with 1 mM norepinephrine, which was shown to be essential for the longterm functional preservation of isolated proximal tubules, 15, 46 was used for the peritubular perfusate and perfused at 10 ml/min. The intracellular buffer capacity was determined by monitoring the cell pH changes to sudden alteration of bath CO 2 tension. The rate of cell pH decrease to bath HCO 3 2 reduction and the buffer capacity were used to calculate the NBCe1 activity as described. 11, 17, 45 Bath HCO 3 2 reduction (from 25 to 12.5 mM) was repeated two or three times during the control period, and only the PTs that show the constant cell pH responses were used for analysis. Valsartan, PD98059, L-NAME, ODQ, KT5823, and isobutylmethylxanthine were used at the concentrations that did not affect the basal NBCe1 activity.
For the analysis of NHE3 activity, cell pH was monitored in the microperfused PT segment as described. 45, 47 Initially, both luminal and bath sides were perfused with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes)-buffered Ringer solution equilibrated with 100% O 2 at approximately 80 nl/min and 10 ml/min, respectively. Thereafter, luminal perfusate was suddenly switched to Na + -free Hepes solution, which replaces Na + in Hepes-buffered Ringer solution with N-methyl-D-glucamine. The resultant decrease in cell pH was shown to reflect the luminal NHE3 activity. 45, 47 Determination of Bicarbonate Absorption Rates (JHCO 3 2
)
The rate of bicarbonate absorption (JHCO 3 2 ) was measured by the stop-flow microspectrofluorometric method as described. 15 Immunoblotting Antibodies against total ERK, phospho (Thr202/Thr204) ERK, GSK-3b, and phospho (Ser9) GSK-3b were from Cell Signaling Technology. For detection of phosphorylation of ERK or GSK-3b, thin slices of kidney n=6.
cortex were obtained. They were divided into pieces of small bundles, consisting mostly of PTs. To reduce the influence of locally produced Ang II, these samples were incubated at 37°C for 40 minutes in DMEM containing 10 27 M captoril under 5% CO 2 as described. 17, 45 After the test agonists were added for 2 minutes, samples were homogenized in ice cold lysis buffer containing 25 mM TriszHCl (pH 7.4), 10 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 100 mM sodium fluoride, 10 mM EDTA, 10 mM EGTA, and 1 mM phenylmethylsulfonyl fluoride, and they were centrifuged at 1000g for 5 minutes. Equal amounts of protein samples were obtained from the cell lysates, separated by SDS-PAGE on acrylamide minigels, and transferred to a nitrocellulose membrane. After incubation in blocking buffer, the membrane was treated with one of the primary antibodies and then, their respective secondary antibodies. The signal was detected by an ECL Plus system (Amersham).
Immunohistochemical Analysis
To examine the intrarenal expression of cGKII, the kidney samples from humans and mice were frozen without fixation and cryosectioned at 10-mm thick; then, they were fixed with buffered 4% paraformaldehyde for 10 minutes. After being washed with PBS, sections were serially incubated with the anti-cGKII antibody (Santa Cruz Biotechnology) for 1 hour and the mixtures of Cy5-conjugated anti-rabbit IgG (Jackson ImmunoResearch Laboratories), Alexa Fluor 568 phalloidin (Molecular Probes), and SYBR Green I (Molecular Probes) for nuclei for 30 minutes at room temperature as described. 45 The specimens were observed with a confocal laser scanning microscope (LSM510META; Carl Zeiss).
Detection of mRNA for cGKII
Total RNA in renal cortex tissues was extracted by ISOGEN (Nippon Gene), and RT-PCR was performed with the SuperScript III One-Step RT-PCR System (Invitrogen). The primers for cGKII were 59-TGA-GAAAAAGCTCATCACAGATGC-39 (sense) and 59-CGGCCAGCA-CAAAGATATGG-39 (antisense). The primers for glyceraldehyde 3-phosphate dehydrogenase were 59-ACCACAGTCCATGCCATCAC-39 (sense) and 59-TCCACCACCCTGTTGCTGTA-39 (antisense).
Determination of Intrarenal Ang II Concentration
Ang II concentration in human kidney cortex was determined as previously described. 42, 49 The kidney samples were homogenized in 100% methanol, evaporated in a vacuum centrifuge, reconstituted in assay buffer, and assayed.
Statistical Analyses
Data are means6SEMs. Significant differences were determined by applying t test or ANOVA with Bonferroni's adjustment as appropriate. Statistical significance was set at P,0.05. 
